指南与共识消化道肿瘤放疗

直肠癌新辅助治疗医院差异及国家指南更新的影响:全国人群研究

Hospital variance in neoadjuvant rectal cancer treatment and the influence of a national guideline update: Results of a nationwide population-based study.
指南 / 共识 · Radiother Oncol · 2020-01-30

该研究基于荷兰癌症登记2009–2016年非转移性直肠癌患者,分析不同风险组新辅助治疗(无、放疗、放化疗)的医院间差异及2014年国家指南更新的影响。共纳入25,306例,病例组合调整后诊断医院在三个风险组均显著影响新辅助治疗实施(p<0.001),但总生存除高危组外未受影响;指南更新后低危组未放疗比例中位数从30.8%升至90.5%(p<0.001)。

要点

  • 病例组合调整后,诊断医院在低、中、高危三组均显著影响新辅助治疗选择(p<0.001)。
  • 仅高危组中放化疗比例最高的医院与更好的5年总生存相关(HR 0.79;p=0.03)。
  • 2014年指南更新后低危组未放疗比例中位数从30.8%升至90.5%(p<0.001)。

核心结论

  • 国家指南修订后治疗模式显著改变,但直肠癌新辅助治疗仍存在较大医院间差异。
  • 高危直肠癌患者在放化疗比例最高的医院治疗生存更好。
  • 为减少治疗差异,需进一步研究差异原因并实施区域化多学科团队(MDT)。

研究设计与样本

  • 基于荷兰癌症登记(Netherlands Cancer Registry)的全国人群研究。
  • 纳入2009–2016年诊断的非转移性直肠癌患者,共25,306例。
  • 按低、中、高危风险组,比较2014年国家指南更新前后各医院新辅助治疗方案(无、放疗、放化疗)的观察分布与病例组合调整分布。

主要发现

  • 病例组合调整后,诊断医院在三个风险组均显著影响新辅助治疗实施(p<0.001)。
  • 总生存总体未受医院影响,但高危组中放化疗比例最高的医院与更好的5年总生存相关(HR 0.79;p=0.03)。
  • 指南修订后,低危组未接受放疗的患者比例中位数从30.8%升至90.5%(p<0.001)。

临床怎么用

  • 关注本院直肠癌新辅助治疗决策与指南推荐的一致性,尤其低危组避免过度放疗。
  • 高危直肠癌应考虑在放化疗经验丰富的医院或区域化MDT框架下治疗。
  • 对医院间治疗差异进行审计与反馈,可能有助于减少不规范变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of this study was to examine the hospital variation in neoadjuvant treatment of rectal cancer according to the different risk groups (low-, intermediate- and high-risk) and evaluate the influence on survival. MATERIALS AND METHODS: Patients with non-metastasized rectal cancer diagnosed between 2009 and 2016 were selected from the Netherlands Cancer Registry. The observed and case-mix adjusted distribution of the different neoadjuvant treatment schemes (none, radiotherapy (RT), chemoradiotherapy (CRT)) by hospital of diagnosis were generated for each risk group in the cohorts before and after the national guideline update of 2014. RESULTS: A total of 25,306 patients were included and after case-mix adjustment, hospital of diagnosis was found to have a significant impact on neoadjuvant treatment administration in each of the three risk groups (p < 0.001). Overall survival was however not influenced, except for the high-risk group where hospitals with highest rates of CRT were associated with a better 5-years overall survival (HR 0.79; p = 0.03). After guideline revision, the rate of patients in the low-risk group who did not undergo RT increased from a median of 30.8% to 90.5% (p < 0.001). CONCLUSION: Although a significant change in treatment was observed after revision of the national guidelines, a wide range of hospital variation still exists in administered neoadjuvant treatment in rectal cancer patients. High-risk rectal cancer patients had a better survival when treated in hospitals with the highest rates of CRT provided. In order to minimize treatment differences, further research into the causes of this variation and implementation of regionalized MDTs may be warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Koëter T, Elferink MA, Verhoeven RHA, et al. Hospital variance in neoadjuvant rectal cancer treatment and the influence of a national guideline update: Results of a nationwide population-based study. Radiother Oncol. 2020. PMID: 32007760. doi:10.1016/j.radonc.2019.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。